Margalee Morgan, L.P.N. Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 33600 Dallas Rd, Hermiston, OR 97838 Phone: 541-567-4429 |
News Archive
GENTAG, Inc., Third Technology Capital Investors, and The CORE Institute are pleased to announce the first fully integrated medical grade wireless monitoring kit for post-surgery applications compatible with the new generation of Near Field Communications (NFC) cell phones. The kit allows patients to self-monitor for excessive swelling in the surgery area or inside casts with their cell phones after hospital discharge (compartment syndrome monitoring).
Titan Pharmaceuticals, Inc. today announced that patient enrollment is now complete in the confirmatory, Phase 3 clinical study of Probuphine for the treatment of opioid addiction. This placebo and active controlled Phase 3 study is being conducted at 20 sites in the United States and the results are expected in the second quarter of 2011, about three months ahead of the original schedule.
MoFlo Astrios EQ, a six-way jet-in-air sorter from Beckman Coulter Life Sciences, delivers patent pending enhanced dual forward scatter (eFSC) technology for simultaneous sorting and detection of particles from 200 nm to 30 µm in diameter. The instrument sets a new standard for flow cytometry core facilities, delivering high-speed cell sorting and micro-particle detection in a single package. Featuring detailed and precise forward scatter resolution, beadless drop sample handling and increased biosafety, Astrios EQ meets a range of analysis needs.
Babies and toddlers with congenital heart disease are at an increased risk of having harmful toxins in their blood, particularly following surgery, according to research by a team at Imperial College London.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 8 days ago